For pediatric patients undergoing chemotherapy treatment for acute myeloid leukemia (AML), dexrazoxane preserved cardiac function without compromising overall survival and event-free survival or increasing noncardiac toxicities, according to a study published in the Journal of Clinical Oncology.1-2
The researchers from the Children’s Hospital of Philadelphia (CHOP) believe that dexrazoxane, a cardioprotective drug, could potentially improve the overall patient survival rate and should be considered for cardioprotection during front-line treatment of AML.
“This study provides important evidence that using dexrazoxane helps prevent heart damage in children undergoing treatment for AML,” senior author of the study Richard Aplenc, MD, PhD, said in a press release.2 “These results have arguably changed the standard of care for pediatric AML treatment.”
The results showed that…
